Clinical trial · Observational
Association Between Screening Behaviors and Lung Cancer Spectrum
A Multicenter, Prospective, Observational Study on the Association Between Real-World Lung Cancer Screening Behaviors and Lung Cancer Disease Spectrum
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The goal of this observational study is to describe the clinical epidemiological characteristics and disease spectrum distribution of newly diagnosed primary lung cancer patients in a real-world setting. The main questions it aims to answer are: What is the current status of lung cancer epidemiology, including age, gender, smoking history, and pathological subtype distribution? How do different lung cancer screening behaviors (e.g., overscreening, underscreening, guideline-concordant, and precision screening) influence the capture rate of the "curative time window" (defined as adenocarcinoma in situ (AIS)/minimally invasive adenocarcinoma (MIA) or pure Ground-Glass Nodules (GGNs) stage)? What are the economic costs and cumulative radiation exposure associated with these different screening patterns? Researchers will compare these screening behavior groups to evaluate the efficacy of the "low-age, low-frequency" screening strategy in capturing early-stage lung cancer. Participants will be asked to: Provide their medical history and detailed records of pre-diagnosis lung cancer screening (including CT scan history). Allow researchers to collect and analyze their clinical, pathological, and radiological data from hospital records and medical databases. Complete a questionnaire regarding their screening history and health-related behaviors.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Cancer | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Epidemiological Characteristics
- timeFrame
- through study completion, an average of 1 year
- description
- Distribution of age, gender, smoking history, and pathological subtypes.
Secondary outcomes (4)
- measure
- Curative Time Window Capture Rate
- timeFrame
- through study completion, an average of 1 year
- description
- The proportion of tumors captured at the AIS/MIA or pure GGN stage
- measure
- Socioeconomic Indicators
- timeFrame
- through study completion, an average of 1 year
- description
- This measure assesses the total direct medical costs. Data are collected through a combination of hospital electronic medical records (EMR) and a structured patient questionnaire. Costs include pre-diagnosis examination expenses (e.g., CT scans, consultations) and post-diagnosis treatment expenses (e.g., surgery, hospitalization, systemic therapy), calculated based on standardized clinical billing data.
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * Histologically confirmed primary lung cancer within the past year (surgical or biopsy pathology). * Patients capable of clearly recalling or providing medical and physical examination history prior to diagnosis. Exclusion Criteria: * Recurrent lung cancer or metastatic lung tumors. * Severe lack of critical clinical data (e.g., inability to provide pathological type or stage). * Patients with cognitive impairment or severe mental illness who cannot cooperate with the questionnaire.
References
Publications (0)
Data not yet available